Takeda Pharmaceutical Company Limit... (TAK)

$12.97

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol TAK
Price $12.97
Beta 0.795
Volume Avg. 2.46M
Market Cap 40.316B
Shares () -
52 Week Range 12.75-16.39
1y Target Est -
DCF Unlevered TAK DCF ->
DCF Levered TAK LDCF ->
ROE 3.49% Neutral
ROA 1.40% Neutral
Operating Margin -
Debt / Equity 122.66% Buy
P/E 29.48 Strong Buy
P/B 0.70 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest TAK news


Mr. Christophe Weber
Healthcare
Drug Manufacturers—Specialty & Generic
New York Stock Exchange

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.